What's Happening?
Insulet Corporation has initiated a pivotal study for its fully closed-loop automated insulin delivery (AID) system for type 2 diabetes. The study, named EVOLVE, aims to demonstrate the safety and efficacy of this system compared to standard therapy.
The system is designed to automatically adjust insulin delivery, eliminating the need for mealtime interaction. The study will enroll up to 350 adults across 40 U.S. sites. Insulet's innovation is intended to improve glycemic outcomes with less burden for users, particularly in primary care settings where most type 2 diabetes patients are managed. The company plans to submit a 510(k) filing to the FDA in 2027 and launch the system in 2028.
Why It's Important?
The development of a fully closed-loop AID system represents a significant advancement in diabetes management technology. By automating insulin delivery, the system could reduce the daily burden on patients and improve adherence to treatment regimens. This innovation aligns with the American Diabetes Association's recommendations and could lead to better health outcomes for the estimated 5.5 million people with type 2 diabetes who require insulin. The study's results could influence future diabetes care guidelines and encourage broader adoption of AID systems, potentially transforming the standard of care for diabetes management.
What's Next?
Following the study, Insulet plans to submit a 510(k) filing to the FDA in 2027, with a commercial launch anticipated in 2028. The company aims to expand access to AID systems, particularly in primary care settings, by streamlining onboarding and training processes. The success of this study could lead to increased adoption of AID systems and further innovations in diabetes care technology.
